SAGE Therapeutics Overview
- Year Founded
-
2010
- Status
-
Public
- Employees
-
487
- Stock Symbol
-
SAGE
- Investments
-
1
- Share Price
-
$6.72
- (As of Monday Closing)
SAGE Therapeutics General Information
Description
Sage Therapeutics Inc is a clinical-stage biopharmaceutical company focused on brain health medicines. The company is targeting diseases and disorders of the brain with three key focus areas: depression, neurology and neuropsychiatry; also targeting two critical central nervous system, or CNS, receptor systems, GABA and NMDA. Its products ZURZUVAE is a medicine for the treatment of postpartum depression, or PPD, in adults, and ZULRESSO is a CIV injection for the treatment of postpartum depression in individuals 15 years old and older. It also has other drugs in its pipeline such as SAGE-324, Dalzanemdor (SAGE-718) among others.
Contact Information
Website
www.sagerx.comCorporate Office
- 55 Cambridge Parkway
- Cambridge, MA 02142
- United States
Corporate Office
- 55 Cambridge Parkway
- Cambridge, MA 02142
- United States
SAGE Therapeutics Stock Performance
(As of Monday Closing)
| Stock Price | Previous Close | 52 wk Range | Market Cap | Shares | Average Volume | EPS |
|---|---|---|---|---|---|---|
| $6.72 | $6.64 | $6.45 - $28.26 | $410M | 61.1M | 743K | -$7.41 |
SAGE Therapeutics Financials Summary
|
In Thousands, USD |
TTM 30-Jun-2024 | FY 2023 31-Dec-2023 | FY 2022 31-Dec-2022 | FY 2021 31-Dec-2021 |
|---|---|---|---|---|
| EV | (60,130) | 431,827 | 889,218 | 682,693 |
| Revenue | 97,244 | 86,455 | 7,686 | 6,308 |
| EBITDA | (481,662) | (578,839) | (545,852) | (456,593) |
| Net Income | (445,673) | (541,489) | (532,784) | (457,892) |
| Total Assets | 697,105 | 882,277 | 1,356,449 | 1,825,288 |
| Total Debt | 1,411 | 5,165 | 12,134 | 18,432 |
SAGE Therapeutics Valuation & Funding
| Deal Type | Date | Amount | Valuation/ EBITDA |
Post-Val | Status | Debt |
|---|
SAGE Therapeutics Cap Table
| Stock | # of Shares Authorized |
Par Value | Dividend Rate (%) | Original Issue Price |
Liquidation | Liquidation Pref. Multiple |
Conversion Price |
% Owned |
|---|
SAGE Therapeutics Comparisons
Industry
Financing
Details
SAGE Therapeutics Competitors (34)
| Company Name | Financing Status | Location | Employees | Total Raised | Last Financing Date/Type | Last Financing Amount |
|---|---|---|---|---|---|---|
| Intracellular Therapies | Formerly VC-backed | New York, NY | ||||
| Vertex Pharmaceuticals | Formerly VC-backed | Boston, MA | ||||
| Praxis (Drug Discovery) | Formerly VC-backed | Boston, MA | ||||
| Ember Therapeutics | Formerly VC-backed | New York, NY | ||||
| Acorda Therapeutics | Corporate Backed or Acquired | Ardsley, NY |
SAGE Therapeutics Related Research & Analysis
Explore institutional-grade private market research from our team of analysts.
-
Verticals
SAGE Therapeutics Patents
SAGE Therapeutics Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| AU-2023220976-A1 | Neuroactive steroids for treatment of cns-related disorders | Pending | 16-Feb-2022 | ||
| CA-3242623-A1 | Neuroactive steroid for the treatment of huntington's disease | Pending | 13-Dec-2021 | ||
| AU-2022409329-A1 | Neuroactive steroid for the treatment of huntington's disease | Pending | 13-Dec-2021 | ||
| EP-4405370-A1 | Deuterated positive nmda-modulating compounds and methods of use thereof | Pending | 22-Sep-2021 | ||
| EP-4392432-A2 | Positive nmda-modulating compounds and methods of use thereof | Pending | 25-Aug-2021 | C07J9/00 |
SAGE Therapeutics Executive Team (21)
| Name | Title | Board Seat |
|---|---|---|
| Barry Greene | Chief Executive Officer & Board Member | |
| Kimi Iguchi | Chief Financial Officer | |
| Matt Lasmanis | Chief Technology and Innovation Officer | |
| Erin Lanciani | Chief People and Experience Officer | |
| Michael Quirk Ph.D | Chief Scientific Officer |
SAGE Therapeutics Board Members (11)
| Name | Representing | Role | Since |
|---|---|---|---|
| Barry Greene | SAGE Therapeutics | Chief Executive Officer & Board Member | |
| Elizabeth Barrett | Self | Board Member | |
| Geno Germano | Self | Board Member | |
| George Golumbeski Ph.D | ARCH Venture Partners | Board Member | |
| James Frates | Self | Board Member |
SAGE Therapeutics Signals
Growth Rate
Growth
Size Multiple
Key Data Points
Similarweb Unique Visitors
Majestic Referring Domains
SAGE Therapeutics Investors
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds | Contact Info |
|---|
SAGE Therapeutics Investments (1)
| Company Name | Deal Date | Deal Type | Deal Size | Industry | Lead Partner |
|---|---|---|---|---|---|
| Ligand Pharmaceuticals | 14-May-2014 | Drug Discovery |
SAGE Therapeutics ESG
Risk Overview
Risk Rating
Updated February, 09, 2024
22.29 | Med Risk
Risk Scale
A lower score indicates better sustainability
Negl
0-10
Low
10-20
Med
20-30
High
30-40
Severe
40+
Exposure
Exposure refers to the extent to which a company is exposed to different material ESG issues
Management
Management is related to actions taken to manage ESG issues
Peers Analysis
Peer performance insights compare the company’s ESG performance to the performance of selected peers to help inform future ESG decisions and drive internal performance improvements.
Global
Covered Companies
of 16,009
Rank
Percentile
Pharmaceuticals
Industry
of 909
Rank
Percentile
Biotechnology
Subindustry
of 404
Rank
Percentile
SAGE Therapeutics Exits (1)
| Company Name | Exit Date | Exit Type | Exit Size | Status | Buyers |
|---|---|---|---|---|---|
| Ligand Pharmaceuticals | 14-May-2014 | Completed |
|
SAGE Therapeutics FAQs
-
When was SAGE Therapeutics founded?
SAGE Therapeutics was founded in 2010.
-
Who is the founder of SAGE Therapeutics?
Douglas Covey Ph.D is the founder of SAGE Therapeutics.
-
Who is the CEO of SAGE Therapeutics?
Barry Greene is the CEO of SAGE Therapeutics.
-
Where is SAGE Therapeutics headquartered?
SAGE Therapeutics is headquartered in Cambridge, MA.
-
What is the size of SAGE Therapeutics?
SAGE Therapeutics has 487 total employees.
-
What industry is SAGE Therapeutics in?
SAGE Therapeutics’s primary industry is Drug Discovery.
-
Is SAGE Therapeutics a private or public company?
SAGE Therapeutics is a Public company.
-
What is SAGE Therapeutics’s stock symbol?
The ticker symbol for SAGE Therapeutics is SAGE.
-
What is the current stock price of SAGE Therapeutics?
As of 07-Oct-2024 the stock price of SAGE Therapeutics is $6.72.
-
What is the current market cap of SAGE Therapeutics?
The current market capitalization of SAGE Therapeutics is $410M.
-
What is SAGE Therapeutics’s current revenue?
The trailing twelve month revenue for SAGE Therapeutics is $97.2M.
-
Who are SAGE Therapeutics’s competitors?
Intracellular Therapies, Vertex Pharmaceuticals, Praxis (Drug Discovery), Ember Therapeutics, and Acorda Therapeutics are some of the 34 competitors of SAGE Therapeutics.
-
What is SAGE Therapeutics’s annual earnings per share (EPS)?
SAGE Therapeutics’s EPS for 12 months was -$7.41.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read blog » -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process »
